Crys Dream's positive for antidepressant
July 13, 2011
« Return to News
The connections of Crys Dream have had their request for a stay on the 90-day suspension the filly trotter received from the Ontario Racing Commission (ORC) as a result of a positive test denied by ORC executive director John L. Blakney. Although Crys Dream was not eligible for this Friday's Delvin Miller Memorial at the Meadowlands, she was entered by trainer Henrik Hollsten into an overnight at the Big M but the entry was denied because of reciprocity from the New Jersey Racing Commission.
Following her victory in the $519,000 Elegantimage final June 18 at Mohawk Racetrack as the odds-on favorite, Crys Dream tested postive for the Class 2 drug O-desmethylvenlafaxine, an antidepressant commonly known as Pristiq. The FDA in the United States approved the drug for antidepressant use in February 2008, and Health Canada approved its use for treatment of depression in Feburary 2009.
ORC rules state that all horses receiving positives for Class 1, 2 or 3 drugs are automatically suspended for 90 days. Currently there are seven other horses beside Crys Dream on the ORC suspended list. With her suspension set to run through Sept. 26, it appears now that Crys Dream will certainly miss the upcoming Hambletonian Oaks at the Meadowlands as well as any possible chance of taking on the colts instead in the Hambletonian.
According to executive director Blakney's ruling, "The Director will only grant a stay upon receipt of a written application with supporting materials and upon being satisfied that granting a stay is in the best interest of racing." The ruling noted that "the Director is not satisfied that granting a stay is in the best interest of racing; take notice that the Director has denied the request for a stay."
Trainer Hollsten is also subject to penalty, and as of Wednesday there has been no hearing scheduled.